$49M round; ex­pe­ri­enced team; A-list VCs — In­ozyme launch­es with rare dis­ease strat­e­gy and a yen for big­ger things to come

It was Ax­el Bolte’s work as a ven­ture part­ner for HBM that orig­i­nal­ly took him to the cam­pus at Yale, with a chance to start meet­ing the sci­en­tists there. And that in­tro­duc­tion even­tu­al­ly led him to Demetrios Brad­dock, who had been do­ing lab work on cal­ci­fi­ca­tion that he’s de­vout­ly hop­ing could have an im­pact on a long line of dis­eases.

“Ul­ti­mate­ly I al­ways want­ed to be di­rect­ly in­volved as an en­tre­pre­neur and op­er­a­tional in com­pa­nies,” says Bolte, “which is what I did be­fore in large or­ga­ni­za­tions.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.